The Noxafil brand and generic had US sales of approximately USD 140.8m MAT for the most recent twelve months ending in February 2022 according to Iqvia.
Dr. Reddy's Posaconazole Delayed-Release Tablets are available in 100 mg strength in bottle count sizes of 60.
Dr. Reddy's Laboratories is an integrated pharmaceutical company, focused on providing affordable medicines.
Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.
Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.
First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus
ARX788 Included in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
Roche first quarter sales up by 10% on strong demand for rapid COVID-19 antigen tests
STENTiT concludes EUR1.8m as part of seed investment round
Dr. Reddy's Laboratories Launches Posaconazole Delayed-Release Tablets in the US Market
Former ViaCyte CEO Paul Laikind Joins Stemson Therapeutics Board of Directors